SCHEMBL105813

SCHEMBL105813

CCCC(=O)CCCC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
CA1 P00915 3/20 0.41
BLM P54132 1/20 0.39
KDM1A O60341 1/20 0.38
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
FFAR3 O14843 2/20 0.36
HDAC3 O15379 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC8 Q9BY41 2/20 0.36
PTPN1 P18031 1/20 0.36
NFKB1 P19838 1/20 0.35
KDM4C Q9H3R0 2/20 0.35
KDM4A O75164 1/20 0.35
PHF8 Q9UPP1 1/20 0.35
KDM2A Q9Y2K7 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26105510 0.93 KMT2A (0.45) MAPTKMT2ACA1BLMCES2
SCHEMBL11550357 0.92 BLM (0.52) MAPTKMT2ACA1BLMKDM1A
SCHEMBL8896470 0.91 KMT2A (0.48) MAPTKMT2ACES2CES1KDM4C
SCHEMBL1243029 0.91 KMT2A (0.48) MAPTKMT2ACES2CES1KDM4C
SCHEMBL14342419 0.91 MAPT (0.46) MAPTKMT2ACA1BLMKDM1A
SCHEMBL5613242 0.90 CA1 (0.48) MAPTKMT2ACA1BLMKDM1A
SCHEMBL15544260 0.88 KMT2A (0.56) MAPTKMT2ACES2CES1PTPN1
SCHEMBL16285823 0.88 BLM (0.44) MAPTKMT2ACA1BLMKDM1A
SCHEMBL8896878 0.86 KMT2A (0.59) MAPTKMT2ACES2CES1PTPN1
SCHEMBL109486 0.85 CA1 (0.50) MAPTKMT2ACA1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-12222653-B2 Method for forming semiconductor structure TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2025-02-11 US disclosed
US-20250000088-A1 ANT CONTROL AGENT AND ANT CONTROL METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-01-02 US disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
EP-4424164-A1 ANT CONTROL AGENT AND ANT CONTROL METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-09-04 EP disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
US-20090036453-A1 Pyrrolopyridazinone Compound UBE INDUSTRIES, LTD. (JP) 2009-02-05 US disclosed
EP-1982986-A1 PYRROLOPYRIDAZINONE COMPOUND Ube Industries, Ltd. (JP) 2008-10-22 EP disclosed
US-4160865-A Asymmetric synthesis HOFFMANN-LA ROCHE INC. (US) 1979-07-10 US disclosed
US-4151360-A Optically active amine salts HOFFMANN-LA ROCHE INC. (US) 1979-04-24 US disclosed
US-4045475-A Optically active alcohols and lower esters thereof HOFFMANN-LA ROCHE INC. (US) 1977-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS MAPT 3235/4885KMT2A 4371/4885CA1 3083/4885
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA MAPT 2745/4885KMT2A 3246/4885CA1 2232/4885
US-20090036453-A1 Pyrrolopyridazinone Compound CBR3, CBR1, CYC1 MAPT 4877/4885KMT2A 3400/4885CA1 2208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.